IDEAYA Biosciences, Inc. Operating Income
IDEAYA Biosciences, Inc. (IDYA) reported Operating Income of -$122.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- IDEAYA Biosciences, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$122.29M.
- IDEAYA Biosciences, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$108.54M.
- IDEAYA Biosciences, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$94.57M.
- IDEAYA Biosciences, Inc. operating income (loss) for the quarter ending 2025-09-30 was $108.45M.
- IDEAYA Biosciences, Inc. operating income (loss) for fiscal 2025 was -$159.31M.
- IDEAYA Biosciences, Inc. operating income (loss) for fiscal 2024 was -$326.98M.
- IDEAYA Biosciences, Inc. operating income (loss) for fiscal 2023 was -$134.43M.
- IDEAYA Biosciences, Inc. operating income (loss) for fiscal 2022 was -$62.50M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$122.29M 10-Q · filed 2026-08-04 | -$230.84M 10-Q · filed 2026-08-04 | -$325.40M derived: sum of 3 quarters · filed 2026-08-04 | -$216.95M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$108.54M 10-Q · filed 2026-05-05 | -$203.11M derived: sum of 2 quarters · filed 2026-05-05 | -$94.66M derived: sum of 3 quarters · filed 2026-05-05 | -$183.47M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$94.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $13.88M derived: sum of 2 quarters · filed 2026-02-17 | -$74.92M derived: sum of 3 quarters · filed 2026-08-04 | -$159.31M 10-K · filed 2026-02-17 |
| 2025-09-30 | $108.45M 10-Q · filed 2025-11-04 | $19.65M derived: sum of 2 quarters · filed 2026-08-04 | -$64.74M 10-Q · filed 2025-11-04 | -$208.88M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$88.81M 10-Q · filed 2026-08-04 | -$173.19M 10-Q · filed 2026-08-04 | -$317.33M derived: sum of 3 quarters · filed 2026-08-04 | -$384.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$84.39M 10-Q · filed 2026-05-05 | -$228.53M derived: sum of 2 quarters · filed 2026-05-05 | -$295.42M derived: sum of 3 quarters · filed 2026-05-05 | -$360.35M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$144.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$211.03M derived: sum of 2 quarters · filed 2026-02-17 | -$275.96M derived: sum of 3 quarters · filed 2026-02-17 | -$326.98M 10-K · filed 2026-02-17 |
| 2024-09-30 | -$66.89M 10-Q · filed 2025-11-04 | -$131.82M derived: sum of 2 quarters · filed 2025-11-04 | -$182.84M 10-Q · filed 2025-11-04 | -$224.75M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | -$64.93M 10-Q · filed 2025-08-05 | -$115.94M 10-Q · filed 2025-08-05 | -$157.86M derived: sum of 3 quarters · filed 2026-02-17 | -$191.39M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | -$51.02M 10-Q · filed 2025-05-06 | -$92.93M derived: sum of 2 quarters · filed 2026-02-17 | -$126.46M derived: sum of 3 quarters · filed 2026-02-17 | -$159.17M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | -$41.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$75.44M derived: sum of 2 quarters · filed 2026-02-17 | -$108.15M derived: sum of 3 quarters · filed 2026-02-17 | -$134.43M 10-K · filed 2026-02-17 |
| 2023-09-30 | -$33.53M 10-Q · filed 2024-11-04 | -$66.23M derived: sum of 2 quarters · filed 2024-11-04 | -$92.51M 10-Q · filed 2024-11-04 | -$118.96M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | -$32.71M 10-Q · filed 2024-08-06 | -$58.99M 10-Q · filed 2024-08-06 | -$85.43M derived: sum of 3 quarters · filed 2025-02-18 | -$84.77M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | -$26.28M 10-Q · filed 2024-05-07 | -$52.72M derived: sum of 2 quarters · filed 2025-02-18 | -$52.06M derived: sum of 3 quarters · filed 2025-02-18 | -$74.56M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | -$26.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$25.78M derived: sum of 2 quarters · filed 2025-02-18 | -$48.28M derived: sum of 3 quarters · filed 2025-02-18 | -$62.50M 10-K · filed 2025-02-18 |
| 2022-09-30 | $660.00K 10-Q · filed 2023-11-07 | -$21.84M derived: sum of 2 quarters · filed 2023-11-07 | -$36.06M 10-Q · filed 2023-11-07 | -$54.43M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$22.50M 10-Q · filed 2023-08-10 | -$36.72M 10-Q · filed 2023-08-10 | -$55.09M derived: sum of 3 quarters · filed 2024-02-20 | -$66.80M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$14.22M 10-Q · filed 2023-05-09 | -$32.59M derived: sum of 2 quarters · filed 2024-02-20 | -$44.30M derived: sum of 3 quarters · filed 2024-02-20 | -$55.35M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$18.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$30.08M derived: sum of 2 quarters · filed 2024-02-20 | -$41.13M derived: sum of 3 quarters · filed 2024-02-20 | -$50.27M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$11.71M 10-Q · filed 2022-11-08 | -$22.76M derived: sum of 2 quarters · filed 2022-11-08 | -$31.90M 10-Q · filed 2022-11-08 | -$37.18M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | -$11.05M 10-Q · filed 2022-08-15 | -$20.19M 10-Q · filed 2022-08-15 | -$25.47M derived: sum of 3 quarters · filed 2023-03-07 | -$30.46M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | -$9.13M 10-Q · filed 2022-05-10 | -$14.41M derived: sum of 2 quarters · filed 2023-03-07 | -$19.41M derived: sum of 3 quarters · filed 2023-03-07 | -$32.00M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | -$5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$10.28M derived: sum of 2 quarters · filed 2023-03-07 | -$22.87M derived: sum of 3 quarters · filed 2023-03-07 | -$35.34M 10-K · filed 2023-03-07 |
| 2020-09-30 | -$5.00M 10-Q · filed 2021-11-15 | -$17.59M derived: sum of 2 quarters · filed 2021-11-15 | -$30.06M 10-Q · filed 2021-11-15 | -$41.38M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-06-30 | -$12.59M 10-Q · filed 2021-08-10 | -$25.07M 10-Q · filed 2021-08-10 | -$36.39M derived: sum of 3 quarters · filed 2022-03-18 | -$48.01M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-03-31 | -$12.48M 10-Q · filed 2021-05-10 | -$23.80M derived: sum of 2 quarters · filed 2022-03-18 | -$35.42M derived: sum of 3 quarters · filed 2022-03-18 | -$46.66M derived: sum of 4 quarters · filed 2022-03-18 |
| 2019-12-31 | -$11.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$22.94M derived: sum of 2 quarters · filed 2022-03-18 | -$34.18M derived: sum of 3 quarters · filed 2022-03-18 | -$44.27M 10-K · filed 2022-03-18 |
| 2019-09-30 | -$11.62M 10-Q · filed 2020-11-12 | -$22.86M derived: sum of 2 quarters · filed 2020-11-12 | -$32.95M 10-Q · filed 2020-11-12 | -$42.09M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-06-30 | -$11.23M 10-Q · filed 2020-08-12 | -$21.33M 10-Q · filed 2020-08-12 | -$30.46M derived: sum of 3 quarters · filed 2021-03-23 | -$44.09M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-03-31 | -$10.09M 10-Q · filed 2020-05-12 | -$19.23M derived: sum of 2 quarters · filed 2021-03-23 | -$32.85M derived: sum of 3 quarters · filed 2021-03-23 | -$40.42M derived: sum of 4 quarters · filed 2021-03-23 |
| 2018-12-31 | -$9.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | -$22.76M derived: sum of 2 quarters · filed 2021-03-23 | -$30.33M derived: sum of 3 quarters · filed 2021-03-23 | -$36.42M 10-K · filed 2021-03-23 |
| 2018-09-30 | -$13.63M 10-Q · filed 2019-11-13 | -$21.20M derived: sum of 2 quarters · filed 2019-11-13 | -$27.28M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$7.57M 10-Q · filed 2019-08-12 | -$13.66M 10-Q · filed 2019-08-12 | ||
| 2017-12-31 | -$14.44M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |